NR 565 Advanced Pharmacology
Fundamentals, Chamberlain University,
, complete examination with answers
and rationales
SECTION I: Pharmacologic Principles & Pharmacokinetics (Questions 1–40)
Question 1
Which pharmacokinetic process describes the movement of a drug from the site
of administration into the bloodstream?
A. Distribution
B. Metabolism
C. Absorption
D. Excretion
Correct Answer: C
Rationale: Absorption is the process by which a drug enters the systemic
circulation from its site of administration. Distribution, metabolism, and excretion
follow absorption. Absorption is influenced by route of administration, drug
formulation, blood flow at the administration site, and drug solubility.
Question 2
What is the primary site of drug metabolism for most oral medications?
A. Kidney
B. Liver
C. Lung
D. Small intestine exclusively
Correct Answer: B
, Rationale: The liver contains high concentrations of cytochrome P450
enzymes responsible for Phase I and Phase II metabolism of the majority of drugs.
While the small intestine and kidneys contribute to metabolism, the liver is the
primary organ for drug biotransformation.
Question 3
Which term describes the fraction of an administered drug that reaches the
systemic circulation unchanged?
A. Bioavailability
B. Half-life
C. Clearance
D. Volume of distribution
Correct Answer: A
Rationale: Bioavailability describes the extent and rate at which the active
drug moiety enters systemic circulation. Intravenous administration has 100%
bioavailability, while oral drugs have reduced bioavailability due to first-pass
metabolism.
Question 4
A patient with liver cirrhosis is prescribed a medication that undergoes extensive
first-pass metabolism. The PMHNP should anticipate:
A. A decreased therapeutic effect
B. An increased risk of toxicity
C. No change in drug response
D. Rapid excretion of the drug
Correct Answer: B
Rationale: Cirrhosis impairs first-pass metabolism, leading to higher
plasma concentrations of the drug and an increased risk of toxicity. Dose
reduction is often necessary in patients with hepatic impairment.
,Question 5
Which parameter reflects the time required for the plasma concentration of a
drug to decrease by 50%?
A. Onset of action
B. Duration of action
C. Half-life
D. Therapeutic index
Correct Answer: C
Rationale: Half-life is the time it takes for the amount of drug in the body
to be reduced by one-half. It determines the dosing interval and the time required
to reach steady state (approximately 4–5 half-lives).
Question 6
A drug with a narrow therapeutic index requires:
A. Routine monitoring of serum drug levels
B. High doses to achieve therapeutic effect
C. No monitoring due to its safety profile
D. Administration without regard to timing
Correct Answer: A
Rationale: A narrow therapeutic index means the difference between
therapeutic and toxic doses is small. Serum levels must be monitored to ensure
safety and efficacy. Examples include warfarin, digoxin, lithium, and phenytoin.
Question 7
Which term refers to the ratio of the dose that produces toxicity to the dose that
produces a therapeutic effect?
, A. Bioavailability
B. Therapeutic index
C. Half-life
D. Clearance
Correct Answer: B
Rationale: The therapeutic index is a measure of drug safety. A higher
therapeutic index indicates a safer drug because there is a larger margin between
therapeutic and toxic doses.
Question 8
A patient taking warfarin is prescribed a drug that inhibits cytochrome P450
enzymes. The PMHNP should anticipate:
A. Decreased warfarin levels
B. Increased warfarin levels and bleeding risk
C. No interaction
D. Increased warfarin metabolism
Correct Answer: B
Rationale: CYP450 inhibitors reduce the metabolism of warfarin, leading
to increased plasma levels and an elevated risk of bleeding. Close monitoring of
INR is essential when adding or removing CYP450 inhibitors. Warfarin is primarily
metabolized by CYP2C9.
Question 9
A drug that binds to a receptor and produces a response that is less than that of a
full agonist, even at maximal concentrations, is known as a:
A. Partial agonist
B. Inverse agonist
C. Competitive antagonist
D. Noncompetitive antagonist
Fundamentals, Chamberlain University,
, complete examination with answers
and rationales
SECTION I: Pharmacologic Principles & Pharmacokinetics (Questions 1–40)
Question 1
Which pharmacokinetic process describes the movement of a drug from the site
of administration into the bloodstream?
A. Distribution
B. Metabolism
C. Absorption
D. Excretion
Correct Answer: C
Rationale: Absorption is the process by which a drug enters the systemic
circulation from its site of administration. Distribution, metabolism, and excretion
follow absorption. Absorption is influenced by route of administration, drug
formulation, blood flow at the administration site, and drug solubility.
Question 2
What is the primary site of drug metabolism for most oral medications?
A. Kidney
B. Liver
C. Lung
D. Small intestine exclusively
Correct Answer: B
, Rationale: The liver contains high concentrations of cytochrome P450
enzymes responsible for Phase I and Phase II metabolism of the majority of drugs.
While the small intestine and kidneys contribute to metabolism, the liver is the
primary organ for drug biotransformation.
Question 3
Which term describes the fraction of an administered drug that reaches the
systemic circulation unchanged?
A. Bioavailability
B. Half-life
C. Clearance
D. Volume of distribution
Correct Answer: A
Rationale: Bioavailability describes the extent and rate at which the active
drug moiety enters systemic circulation. Intravenous administration has 100%
bioavailability, while oral drugs have reduced bioavailability due to first-pass
metabolism.
Question 4
A patient with liver cirrhosis is prescribed a medication that undergoes extensive
first-pass metabolism. The PMHNP should anticipate:
A. A decreased therapeutic effect
B. An increased risk of toxicity
C. No change in drug response
D. Rapid excretion of the drug
Correct Answer: B
Rationale: Cirrhosis impairs first-pass metabolism, leading to higher
plasma concentrations of the drug and an increased risk of toxicity. Dose
reduction is often necessary in patients with hepatic impairment.
,Question 5
Which parameter reflects the time required for the plasma concentration of a
drug to decrease by 50%?
A. Onset of action
B. Duration of action
C. Half-life
D. Therapeutic index
Correct Answer: C
Rationale: Half-life is the time it takes for the amount of drug in the body
to be reduced by one-half. It determines the dosing interval and the time required
to reach steady state (approximately 4–5 half-lives).
Question 6
A drug with a narrow therapeutic index requires:
A. Routine monitoring of serum drug levels
B. High doses to achieve therapeutic effect
C. No monitoring due to its safety profile
D. Administration without regard to timing
Correct Answer: A
Rationale: A narrow therapeutic index means the difference between
therapeutic and toxic doses is small. Serum levels must be monitored to ensure
safety and efficacy. Examples include warfarin, digoxin, lithium, and phenytoin.
Question 7
Which term refers to the ratio of the dose that produces toxicity to the dose that
produces a therapeutic effect?
, A. Bioavailability
B. Therapeutic index
C. Half-life
D. Clearance
Correct Answer: B
Rationale: The therapeutic index is a measure of drug safety. A higher
therapeutic index indicates a safer drug because there is a larger margin between
therapeutic and toxic doses.
Question 8
A patient taking warfarin is prescribed a drug that inhibits cytochrome P450
enzymes. The PMHNP should anticipate:
A. Decreased warfarin levels
B. Increased warfarin levels and bleeding risk
C. No interaction
D. Increased warfarin metabolism
Correct Answer: B
Rationale: CYP450 inhibitors reduce the metabolism of warfarin, leading
to increased plasma levels and an elevated risk of bleeding. Close monitoring of
INR is essential when adding or removing CYP450 inhibitors. Warfarin is primarily
metabolized by CYP2C9.
Question 9
A drug that binds to a receptor and produces a response that is less than that of a
full agonist, even at maximal concentrations, is known as a:
A. Partial agonist
B. Inverse agonist
C. Competitive antagonist
D. Noncompetitive antagonist
